Gilead Sciences, Inc. (NASDAQ: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1490) evaluating the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

New Gilead Sciences (GILD) HIV Concerns 'Overdone' - RBCOctober 31, 2018 12:24 PM Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV TherapyOctober 30, 2018 6:36 AM Gilead Sciences (GILD) PT Raised to $88 at Cantor FitzgeraldOctober 26, 2018 10:49 AM Gilead Sciences (GILD) PT Lowered to $87 at RBC CapitalOctober 26, 2018 7:24 AM Piper Jaffray Downgrades Gilead Sciences (GILD) to NeutralOctober 26, 2018 4:41 AM Gilead Sciences (GILD) PT Raised to $95 at BarclaysOctober 26, 2018 3:57 AM